With respect to T2DM medications, 74.3% received metformin, 14.3% received sulfonylurea, 2.9% received glinide, 31.1% received pioglitazone, and 5.7% of the patients received insulin treatment. The gene discussed is INS; the disease is type 2 diabetes mellitus.